Table 1.
Study | Arms | Patients | Overall response rate (%) | P value | Median progression-free survival (months) | HR (P value) | Overall survival (months) | HR (P value) |
---|---|---|---|---|---|---|---|---|
AVF2119g | Capecitabine + placebo | 230 | 9.1 | 0.001 | 4.2 | 0.98 (0.857) | 14.5 | Not reported |
Capecitabine + bevacizumab | 232 | 19.8 | 4.89 | 15.1 | ||||
E2100 | Paclitaxel | 326 | 22.2 | <0.0001 | 5.8 | 0.483 (<0.0001) | 25.2 | 0.88 (0.16) |
Paclitaxel + bevacizumab | 347 | 48.9 | 11.3 | 26.7 | ||||
AVADO | Docetaxel + placebo | 241 | 46.4 | Placebo vs. bev7.5: 0.07 | 8.1 | Placebo vs. bev7.5: 0.8 (0.045) | 31.9 | Placebo vs. bev7.5: 1.05 (0.72) |
Docetaxel + bevacizumab (7.5 mg/kg) | 248 | 55.2 | 9.0 | 30.8 | ||||
Docetaxel + bevacizumab (15 mg/kg) | 247 | 64.1 | Placebo vs. bev15: <0.001 | 10.0 | Placebo vs. bev15: 0.67 (<0.001) | 30.2 | Placebo vs. bev15: 1.03 (0.85) | |
RIBBON-1 | Capecitabine + placebo | 206 | 23.6 | 0.0097 | 5.7 | 0.69 (<0.001) | 21.2 | 0.85 (0.27) |
Capecitabine + bevacizumab | 409 | 35.4 | 8.6 | 29.0 | ||||
Anthracycline/taxane + placebo | 207 | 37.9 | 0.0054 | 8.0 | 0.64 (<0.001) | 23.8 | 1.03 (0.83) | |
Anthracycline/taxane + bevacizumab | 415 | 51.3 | 9.2 | 25.2 | ||||
RIBBON-2 | Taxane or gemcitabine or capecitabine or vinorelbine (chemo) + placebo | 225 | 29.6 | 0.0193 | 5.1 | 0.78 (0.0072) | 16.4 | 0.90 (0.37) |
Chemo + bevacizumab | 459 | 39.5 | 7.2 | 18.0 |